Carisoprodol

Carisoprodol
Molecular structure of carisoprodol
3D representation of a carisoprodol molecule
Clinical data
Pronunciation/kəˌraɪsəˈproʊdɒl/
kə-RY-sə-PROH-dol
Trade namesSoma, others
AHFS/Drugs.comMonograph
MedlinePlusa682578
License data
Addiction
liability
Moderate - High
Routes of
administration
By mouth
Drug classMuscle relaxant
ATC code
Legal status
Legal status
Pharmacokinetic data
Protein binding60%
MetabolismLiver (CYP2C19-mediated)
MetabolitesMeprobamate
Onset of actionRapid (30 minutes)
Elimination half-life2.5 hours [12 hours]
ExcretionKidney
Identifiers
  • (RS)-2-{[(aminocarbonyl)oxy]methyl}-2-methylpentyl isopropylcarbamate
CAS Number
PubChem CID
IUPHAR/BPS
DrugBank
ChemSpider
UNII
KEGG
ChEBI
ChEMBL
CompTox Dashboard (EPA)
ECHA InfoCard100.001.017
Chemical and physical data
FormulaC12H24N2O4
Molar mass260.334 g·mol−1
3D model (JSmol)
  • O=C(N)OCC(C)(CCC)COC(=O)NC(C)C
  • InChI=1S/C12H24N2O4/c1-5-6-12(4,7-17-10(13)15)8-18-11(16)14-9(2)3/h9H,5-8H2,1-4H3,(H2,13,15)(H,14,16) checkY
  • Key:OFZCIYFFPZCNJE-UHFFFAOYSA-N checkY
  (verify)

Carisoprodol, sold under the brand name Soma among others, is an oral medication used for musculoskeletal pain. Effects generally begin within half an hour and last up to six hours.

Common side effects include headache, dizziness, and sleepiness. Serious side effects may include addiction, allergic reactions, and seizures. In people with a sulfa allergy certain formulations may cause problems. Safety during pregnancy and breastfeeding is not clear. How it works is not clear. Some of its effects are believed to occur after metabolic conversion into meprobamate, carisoprodol's main active metabolite.

Carisoprodol was approved for medical use in the United States in 1959. Its approval in the European Union was withdrawn in 2008. It is available as a generic medication. In 2019, it was the 343rd most commonly prescribed medication in the United States, with more than 800,000 prescriptions. In the United States, it was unscheduled until 2012, when it became a Schedule IV controlled substance.